Why VCs are playing the royalty game; Canada approves Jetrea;

@FierceBiotech: We're looking for the fiercest women in biotech for our 2013 report. Editor's note | Nomination form | Follow @FierceBiotech

@JohnCFierce: MannKind rewarded for positive Afrezza data with $40M financing. Report | Follow @JohnCFierce

@RyanMFierce: Scientists found a causal link between a tooth cavity bacterium and colon cancer in mice, potential drug target. More from TheScientist | Follow @RyanMFierce

@EmilyMFierce: SeattleBioMed wins $16M NIH grant for tuberculosis research. ICYMI yesterday from FierceBiotechResearch.com | Follow @EmilyMFierce

> The InVivo Blog analyzed the unlikely role of a pair of VC firms, Clarus and Aisling, in the purchase of royalty rights from Quest Diagnostics for Johnson & Johnson's ($JNJ) and Pharmacylics' potential blockbuster leukemia drug ibrutinib. Blog

> Health Canada has approved Jetrea from ThromboGenics and Alcon for symptomatic vitreomacular adhesion. Release

Medical Device News

@FierceMedDev: UPDATED: Bard ordered to pay $2M in vaginal mesh trial defeat. News | Follow @FierceMedDev

@DamianFierce: A global cybersecurity outfit is lending a hand to the medical device industry. Article | Follow @DamianFierce

@MarkHFierce: Heathrow Airport have been warned that female terrorists might strike with breast implant explosives. Report | Follow @MarkHFierce

@MichaelGFierce: ICYMI: St. Jude nets FDA approval for low-radiation ablation catheters. Article | Follow @MichaelGFierce

> China targets medical device misuse. Item

> Coloplast feels weight of rival's vaginal mesh legal woes. Story

> Gene By Gene joins Ambry to fight Myriad's Dx 'monopoly.' Report

Pharma News

@FiercePharma: Trending online: Which are pharma's top 4 innovators? Hint: It's not the big guys. More | Follow @FiercePharma

@EricPFierce: FDA wants help figuring out how to stop addicts from getting to the APIs in opioid painkillers. Story from FiercePharmaManufacturing.com | Follow @EricPFierce

@CarlyHFierce: The latest in India vs. Big Pharma IP developments: Roche won't pursue Herceptin patents in India. Article | Follow @CarlyHFierce

> NICE denies Pfizer lung cancer drug in final guidance. Report

> Stada quickly pulls off deal for OTC maker Thorton & Ross. Article

> Easing U.S. drug spending gives Sanofi, Novo room to raise insulin prices. Story

And Finally… Scientists reported causal links between a mouth microbe and colon cancer. Article